Abstract
A randomised double-blind comparison of three treatment strategies in 533 patients with mild-to-moderate hypertension over 6-9 months. The low-dose perindopril/indapamide (PER/IND) combination (2 mg and 0.625 mg, respectively) daily resulted in a significantly better blood pressure control and systolic blood pressure decrease. In addition, the low-dose PER/IND combination showed superior efficacy/safety criteria than the sequential strategy of atenolol (50 mg) then losartan (50 mg) then amlodipine (5 mg), and the step-by-step strategy of valsartan (40 mg then 80 mg then 80 mg plus hydrochlorothiazide 12.5 mg).
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Antihypertensive Agents / administration & dosage*
-
Antihypertensive Agents / therapeutic use*
-
Atenolol / therapeutic use
-
Blood Pressure / drug effects
-
Diuretics / administration & dosage*
-
Diuretics / therapeutic use*
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hydrochlorothiazide / therapeutic use
-
Hypertension / drug therapy*
-
Indapamide / administration & dosage*
-
Indapamide / therapeutic use*
-
Male
-
Middle Aged
-
Perindopril / administration & dosage*
-
Perindopril / therapeutic use*
-
Sodium Chloride Symporter Inhibitors / therapeutic use
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Diuretics
-
Sodium Chloride Symporter Inhibitors
-
Hydrochlorothiazide
-
Atenolol
-
Indapamide
-
Perindopril